{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:48Z","timestamp":1791828588334,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:00:00Z","timestamp":1457654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00296-016-3452-0","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T02:20:27Z","timestamp":1457662827000},"page":"643-651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern\/Central Europe, Latin America, and Asia"],"prefix":"10.1007","volume":"36","author":[{"given":"Nemanja","family":"Damjanov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed Al","family":"Shehhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Kotak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Burgos-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Shirazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustratios","family":"Bananis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Szumski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndon J. Q.","family":"Llamado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,11]]},"reference":[{"issue":"Suppl 3","key":"3452_CR1","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","volume":"61","author":"J Sieper","year":"2002","unstructured":"Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(Suppl 3):iii8\u2013iii18","journal-title":"Ann Rheum Dis"},{"key":"3452_CR2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379\u20131390","journal-title":"Lancet"},{"key":"3452_CR3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ (2014) Global prevalence of ankylosing spondylitis. Rheumatology 53:650\u2013657","journal-title":"Rheumatology"},{"key":"3452_CR4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/RHU.0b013e3182862e65","volume":"19","author":"I Pel\u00e1ez-Ballestas","year":"2013","unstructured":"Pel\u00e1ez-Ballestas I, Navarro-Zarza JE, Julian B et al (2013) A community-based study on the prevalence of spondyloarthritis and inflammatory back pain in Mexicans. J Clin Rheumatol 19:57\u201361","journal-title":"J Clin Rheumatol"},{"key":"3452_CR5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442\u2013452","journal-title":"Ann Rheum Dis"},{"key":"3452_CR6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1521-6942(02)90245-7","volume":"16","author":"J Braun","year":"2002","unstructured":"Braun J, Breban M, Maksymowych WP (2002) Therapy for ankylosing spondylitis: new treatment modalities. Best Pract Res Clin Rheumatol 16:631\u2013651","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3452_CR7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2011","unstructured":"Braun J, van der Horst-Bruinsma IE, Huang F et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63:1543\u20131551","journal-title":"Arthritis Rheum"},{"key":"3452_CR8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.21563","volume":"54","author":"H Haibel","year":"2006","unstructured":"Haibel H, Rudwaleit M, Brandt HC et al (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54:678\u2013681","journal-title":"Arthritis Rheum"},{"key":"3452_CR9","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136\u20132146","journal-title":"Arthritis Rheum"},{"key":"3452_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A et al (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 73:39\u201347","journal-title":"Ann Rheum Dis"},{"key":"3452_CR11","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230\u20133236","journal-title":"Arthritis Rheum"},{"key":"3452_CR12","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594\u20131600","journal-title":"Ann Rheum Dis"},{"key":"3452_CR13","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/art.30263","volume":"63","author":"P Emery","year":"2011","unstructured":"Emery P, Fleischmann R, van der Heijde D et al (2011) The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 63:1200\u20131210","journal-title":"Arthritis Rheum"},{"key":"3452_CR14","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase iii trial. Arthritis Rheum 58:3402\u20133412","journal-title":"Arthritis Rheum"},{"key":"3452_CR15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"3452_CR16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (assert). Arthritis Rheum 52:582\u2013591","journal-title":"Arthritis Rheum"},{"key":"3452_CR17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X et al (2011) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896\u2013904","journal-title":"Ann Rheum Dis"},{"key":"3452_CR18","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876\u20131886","journal-title":"Arthritis Rheum"},{"key":"3452_CR19","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","volume":"63","author":"J Brandt","year":"2004","unstructured":"Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J (2004) Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 63:1438\u20131444","journal-title":"Ann Rheum Dis"},{"key":"3452_CR20","first-page":"1694","volume":"21","author":"TR Jenkinson","year":"1994","unstructured":"Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (as). The bath as metrology index. J Rheumatol 21:1694\u20131698","journal-title":"J Rheumatol"},{"key":"3452_CR21","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"3452_CR22","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"3452_CR23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jbspin.2013.01.003","volume":"80","author":"M Godfrin-Valnet","year":"2013","unstructured":"Godfrin-Valnet M, Prati C, Puyraveau M, Toussirot E, Letho-Gyselink H, Wendling D (2013) Evaluation of spondylarthritis activity by patients and physicians: asdas, basdai, pass, and flares in 200 patients. Joint Bone Spine 80:393\u2013398","journal-title":"Joint Bone Spine"},{"key":"3452_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group (1990) Euroqol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"key":"3452_CR25","doi-asserted-by":"crossref","unstructured":"Ware JE, Kosinski M (2001) Interpreting SF-36 summary health measures: a response. Qual Life Res 10:405\u2013413; discussion 415\u2013420","DOI":"10.1023\/A:1012588218728"},{"key":"3452_CR26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl 1","key":"3452_CR27","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s10198-014-0592-6","volume":"15","author":"M P\u00e9ntek","year":"2014","unstructured":"P\u00e9ntek M, Po\u00f3r G, Wiland P et al (2014) Biological therapy in inflammatory rheumatic diseases: issues in central and eastern european countries. Eur J Health Econ 15(Suppl 1):S35\u2013S43","journal-title":"Eur J Health Econ"},{"key":"3452_CR28","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s10067-012-2058-5","volume":"31","author":"B Rachid","year":"2012","unstructured":"Rachid B, El Zorkany B, Youseif E, Tikly M (2012) Early diagnosis and treatment of ankylosing spondylitis in Africa and the middle east. Clin Rheumatol 31:1633\u20131639","journal-title":"Clin Rheumatol"},{"key":"3452_CR29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10067-012-2137-7","volume":"32","author":"M Hammoudeh","year":"2013","unstructured":"Hammoudeh M, Alarfaj A, Chen DY, Djoudi H, Youseif E, Zhu J (2013) Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the middle east, and Asia: focus on severe infections and tuberculosis. Clin Rheumatol 32:293\u2013300","journal-title":"Clin Rheumatol"},{"key":"3452_CR30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/rheumatology\/kep393","volume":"49","author":"M Benhamou","year":"2010","unstructured":"Benhamou M, Gossec L, Dougados M (2010) Clinical relevance of c-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs\/coxibs\u2019 treatment effect on c-reactive protein. Rheumatology 49:536\u2013541","journal-title":"Rheumatology"},{"key":"3452_CR31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.berh.2010.05.009","volume":"24","author":"K Vlam de","year":"2010","unstructured":"de Vlam K (2010) Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol 24:671\u2013682","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3452_CR32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/ard.46.4.273","volume":"46","author":"KM Sanders","year":"1987","unstructured":"Sanders KM, Hertzman A, Escobar MR, Littman BH (1987) Correlation of immunoglobulin and c reactive protein levels in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 46:273\u2013276","journal-title":"Ann Rheum Dis"},{"key":"3452_CR33","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger N, van der Heijde D, Inman RD et al (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70:973\u2013981","journal-title":"Ann Rheum Dis"},{"key":"3452_CR34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/acr.20685","volume":"64","author":"NA Khan","year":"2012","unstructured":"Khan NA, Spencer HJ, Abda E et al (2012) Determinants of discordance in patients\u2019 and physicians\u2019 rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 64:206\u2013214","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3452_CR35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/RHU.0b013e3182a2164f","volume":"19","author":"JA Markenson","year":"2013","unstructured":"Markenson JA, Koenig AS, Feng JY et al (2013) Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a retrospective analysis from the radius cohort. J Clin Rheumatol 19:317\u2013323","journal-title":"J Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-016-3452-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3452-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:28:36Z","timestamp":1559028516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-016-3452-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3452"],"URL":"https:\/\/doi.org\/10.1007\/s00296-016-3452-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,11]]}}}